LISBON, Portugal (AP) — The goals are flying in again for Arsenal — and it just happens to coincide with the return from injury of Martin Odegaard. Make that eight goals in two games since the international break for Arsenal after its 5-1 hammering of Sporting Lisbon in the Champions League on Tuesday, tying the English team’s heaviest ever away win in the competition. Odegaard is back in Arsenal’s team after missing two months with an ankle injury . In that time, Mikel Arteta’s attack stuttered, with a 2-0 loss to Bournemouth and a 1-0 defeat at Newcastle dropping the Gunners well off the pace in the Premier League. There was also a 0-0 draw at Atalanta in the Champions League as well as a 1-0 loss to Inter Milan last month, when Odegaard made his comeback from injury as an 89th-minute substitute. Since then, Arsenal hasn’t lost and the goals have returned. After a 3-0 win over Nottingham Forest on Saturday came the cruise in Lisbon — and Odegaard was at the heart of everything as Sporting’s unbeaten start to the season came to an end. “He’s an unbelievable player,” Arsenal winger Bukayo Saka said of Odegaard. “The day he returned, there was a big smile on my face. You can see the chemistry we have. I hope he stays fit for the rest of the season.” Odegaard was involved in the build-up to Arsenal’s first two goals against Sporting — scored by Gabriel Martinelli and Kai Havertz — and was fouled to win the penalty converted by Saka in the 65th to restore Arsenal’s three-goal lead at 4-1. Odegaard was seen flexing his leg after that but continued untroubled and was substituted in the 78th minute. The last thing Arteta would want now is another injury to Odegaard as Arsenal attempts to reel in first-place Liverpool in the Premier League. Liverpool is already nine points ahead of fourth-place Arsenal after 12 games. ___ AP soccer: https://apnews.com/hub/soccer The Associated PressAlgert Global LLC Takes $728,000 Position in Lattice Semiconductor Co. (NASDAQ:LSCC)
Angela Merkel recounts being the first and only in new memoir
SAN JOSE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Cisco (NASDAQ: CSCO) will host its 2024 Annual Meeting of Stockholders on Monday, December 9, 2024 , beginning at 8:00 a.m. PST via audio webcast. Participants will include Cisco Chair and CEO Chuck Robbins . What: 2024 Cisco Virtual Annual Meeting of Stockholders When: Monday, December 9, 2024, 8:00 a.m. PST Listen and Watch: A live audio (including closed captioning) webcast of the meeting with synchronized slides will be available online. Cisco stockholders of record as of October 10, 2024 , can vote and ask questions online during the meeting. Visit www.virtualshareholdermeeting.com/CSCO2024 to attend. Online Annual Report: View Cisco's 2024 Annual Report and Proxy at www.cisco.com/c/en/us/about/annual-reports.html Replay: A replay of the Annual Stockholder Meeting with synchronized slides will be available on the Cisco Investor Relations website at investor.cisco.com within 24 hours of the conclusion. About Cisco Cisco (NASDAQ: CSCO) is the worldwide technology leader that securely connects everything to make anything possible. Our purpose is to power an inclusive future for all by helping our customers reimagine their applications, power hybrid work, secure their enterprise, transform their infrastructure, and meet their sustainability goals. Discover more on The Newsroom and follow us on X at @Cisco . Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks . Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. Investor Relations Contact: Press Contact: Sami Badri Robyn Blum Cisco Cisco 469-420-4834 408-930-8548 sambadri@cisco.com rojenkin@cisco.com View original content to download multimedia: https://www.prnewswire.com/news-releases/cisco-to-host-2024-virtual-annual-meeting-of-stockholders-302316943.html SOURCE Cisco Systems, Inc.Preview: Qarabag FK vs. Lyon - prediction, team news, lineups
Drug company executives had hoped that a second Trump administration would be staffed by friendly health policy officials who would reduce regulation and help their industry boom. But some of President-elect Donald Trump’s proposed nominees are instead alarming drugmakers, according to interviews with people in the industry. For health secretary, Trump chose Robert F. Kennedy Jr., a longtime vaccine skeptic with no medical or public health training who has accused drug companies of the “mass poisoning” of Americans. Trump’s pick to lead the Centers for Disease Control and Prevention is Dr. Dave Weldon, a former Congress member from Florida who raised doubts about vaccines and pushed to move most vaccine safety research from the agency. And Trump’s choice to run the Centers for Medicare and Medicaid Services, former television host Dr. Mehmet Oz, has scant experience in managing a large bureaucracy like the one he may now oversee; the agency is in charge of health care programs that cover more than 150 million Americans. In Trump’s first term as president, pharmaceutical executives largely cheered his health policy nominees. They had ties to the moderate wing of the Republican Party and decades of conventional experience, including at major drug companies. John LaMattina, who was once the top scientist at Pfizer and is now a senior partner at PureTech Health, a firm that creates biotech startups, said of those officials, “You could disagree with them, but at least there’s a certain knowledge base, and they’ve given serious thought to these issues.” He added, “We’re now seeing some people without any sort of background, and that’s worrisome.” The implications remain unclear for Americans who rely on medications or on widespread immunity from diseases that, for now, are rare. Some in the Trump administration want to speed drug approvals, potentially seeding the market with drugs of uncertain effectiveness. Kennedy has in some forums called for more independent safety reviews of established vaccines, and at other times, he has demanded fewer constraints on unconventional and unproven treatments. But Kennedy has also tapped in to veins of outrage among consumers and lawmakers, who have long vilified drug companies for setting high prices on certain drugs and reaping billions of dollars in profits rather than putting patients first. In choosing such a vociferous critic as Kennedy, the president-elect stunned the sector, causing vaccine and biotechnology stocks to plummet temporarily. And though Kennedy most recently said that he would not take vaccines away from Americans who want them, even a modest reduction in the number of people receiving certain shots could spook investors and translate into hundreds of millions of dollars of lost revenue. The industry is also concerned that drug approvals could be delayed if Kennedy makes good on his threats to fire drug regulators, or if they quit in droves to avoid working under his leadership. “There was cautious optimism on Trump when he won, and that was very rapidly replaced with concern over RFK Jr.,” said Brian Skorney, a drug industry analyst at the investment bank Baird. Drug companies’ political action committees made millions of dollars in contributions to Democrats and Republicans this election cycle, and the industry’s lobbying groups can wield considerable influence over policy and legislation. Top pharmaceutical executives have said little publicly about Trump’s picks for health policy positions, seeking to avoid alienating the people who would regulate them. Their lobbying groups have publicly issued polite statements saying they want to work constructively with the administration. But Derek Lowe, a longtime pharmaceutical researcher and industry commentator, has criticized Kennedy on his blog, calling him “a demagogue whose positions on key public health issues like vaccination are nothing short of disastrous.” “You really can’t engage with someone like that. There is no common ground,” Lowe said in an interview. Drug industry officials have a long list of concerns about Kennedy, who did not return a request for comment for this article. They are particularly worried that he could seek to undermine childhood vaccines; one way would be for him to push to revise the government’s recommendations on immunizations. Kennedy has also called for overturning legal protections that shield vaccine makers from litigation when people are seriously harmed by vaccines — a change that would upend an established compensation program and could expose the industry to costly lawsuits. The stakes appear to be highest for companies that make vaccines. About a fifth of Merck’s revenue comes from two types of vaccines that Kennedy has targeted: a vaccine against the human papillomavirus that has averted thousands of cancer cases, and the shots that children receive to protect them against measles, mumps and rubella. (Merck declined to comment.) Vaccine sales represent about 3% of the industry’s overall prescription drug revenues, according to IQVIA, an industry data provider. With some exceptions, vaccines tend to generate relatively low returns compared with profits from more expensive products used for diseases like cancer and arthritis. Drug manufacturers also fear the effect Kennedy could have at the Food and Drug Administration. They often complain that the agency can be too onerous, but their business model is reliant on a well-staffed FDA that can weed out would-be competitors that haven’t met its standards for safety and effectiveness. Kennedy regularly lambastes the FDA as “corrupt” and too close to the drug industry. He has denounced the fees the agency receives from makers of medical devices and drugs, which make up about half of its $7.2 billion annual budget. It’s unclear how Kennedy’s views will mesh with those of Jim O’Neill, a Silicon Valley investor and former government official who would serve as his deputy if he is confirmed. O’Neill, a former top aide to billionaire Peter Thiel, has called for approving drugs once they’ve been shown to be safe but before they have been shown to be effective. That idea goes well beyond the deregulation favored by most pharmaceutical executives. Karoline Leavitt, a spokesperson for Trump’s transition who will be his press secretary, described the president-elect’s choices for administration posts as “highly qualified” and reflective of “his priority to put America First.” Although lawmakers in both parties frequently criticize the drug industry for charging high prices, Kennedy paints pharmaceutical companies in a much harsher light. In an interview last year, Kennedy called vaccine makers “the most corrupt companies in the world” and “serial felons.” He has advanced falsehoods about the science underlying some of the industry’s most influential products, suggesting that vaccines cause autism and that HIV may not be the true cause of AIDS. He has embraced an increasingly popular notion that healthy food and lifestyle changes — not pharmaceutical products — will heal sick people. Referring to drug companies, he wrote on the social platform X this year, “The sicker we get the richer and more powerful they become.” “His view of our world seems to be that everything is a conspiracy,” said Brad Loncar, a former biotech investor who now runs BiotechTV, an industry media company. “If you really know our industry, it’s made up of well-intentioned, smart people, and it’s one of the most innovative sectors of our entire economy.” Pharmaceutical officials were relieved by Trump’s pick to lead the FDA, Dr. Martin Makary, who has a contrarian bent but has been aligned with scientific consensus on vaccine safety and is not seen as a threat to unwind the status quo. Drug companies hope to have an ally in Vivek Ramaswamy, who made his fortune as a biotechnology executive and has been named to lead a government efficiency effort alongside Elon Musk. Ramaswamy has been critical of what he describes as regulatory red tape that slows new drug approvals. And O’Neill, the president-elect’s choice for deputy health secretary, has close ties to some biotechnology and medical technology companies, though he is less well-connected to major industry players. Bracing for the potential of public attacks and new proposals that could hurt their bottom lines, drug companies are said to be reaching out to contacts close to Trump in hopes of influencing the incoming administration. Some are also considering new ways to defend their businesses from government initiatives they consider detrimental. “There’s no playbook for dealing with these disruptive figures like Kennedy,” said Sam Geduldig, managing partner of the right-leaning lobbying firm CGCN Group. Other lobbyists said they are instructing pharmaceutical clients not to hit the panic button yet. Once Congress returns after the Thanksgiving break, Kennedy is expected to make the rounds on Capitol Hill. He could face trouble winning the support he needs from Senate Republicans to be confirmed because of his record on vaccines, his past support for abortion rights and his ideas about overhauling the food system. Drug industry officials have long regarded Trump as a wild card, just as likely to be a boon as a foe. In 2020, the Trump administration’s Operation Warp Speed worked closely with drugmakers and poured billions of dollars into producing highly effective COVID shots in record time, saving countless lives. Trump’s pandemic-era health secretary, Alex Azar, spoke with admiration that year about “our partners in the private sector.” But this year, Trump spoke little about Operation Warp Speed. With some exceptions, the drug industry has been in something of a slump since the heights of the pandemic, when it enjoyed a boost in its public image, and investors eager to get in on huge gains poured money into drug stocks. But trust in vaccines and public health institutions has eroded at the same time as the bubble in the biotech markets has deflated. Among major COVID vaccine makers, Moderna’s stock price is down tenfold, and Pfizer’s stock price has fallen by half, from their high-water marks in 2021. An index of smaller biotechnology stocks is down by close to half. Drug company officials still see opportunities to benefit from Trump’s win. The industry is looking forward to Trump replacing Lina Khan, the chair of the Federal Trade Commission, as he is expected to do. She has been aggressive in taking on big business, including pharma. The industry is also hopeful that Trump could help reverse its worst policy defeat in recent memory. Under the 2022 Inflation Reduction Act, President Joe Biden’s signature policy achievement, Democratic lawmakers empowered Medicare to directly negotiate the prices of certain prescription drugs — cutting into manufacturers’ profits and raising the specter of similar price cuts in the commercial market. Republicans in Congress have said that they want to repeal the negotiation program. This article originally appeared in The New York Times . © 2024 The New York Times Company